MOUNJARO PEN

Tirzepatide — Compound Overview

Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is one of the most extensively studied incretin-pathway compounds of the past decade and serves as a key reference molecule in metabolic signalling research.

Status distinction

Tirzepatide is the active substance in authorised medicinal products in several jurisdictions. VQ Health supplies this material strictly as an in-vitro research reference compound. Nothing here relates to authorised medicinal use, and no dosing or administration information is provided.

Research Context

Incretin biology became a major research focus after the characterisation of GLP-1 and GIP as gut-derived hormones that amplify glucose-dependent insulin secretion. Dual-receptor agonism — engaging both GIP and GLP-1 receptors with a single molecule — was investigated as a way to probe how the two pathways interact. Tirzepatide emerged from that programme and has been evaluated across a large phase 3 clinical trial programme (the SURPASS and SURMOUNT series), making it one of the richest datasets in modern metabolic research.

Preclinical vs clinical evidence

• Established (peer-reviewed clinical trials): receptor pharmacology, glucose-lowering and body-weight effects in the studied clinical populations, pharmacokinetic profile.
• Investigational / preclinical: adipose-tissue signalling effects of GIP agonism, central appetite-pathway interactions, long-acting receptor occupancy models. These remain active study areas, not settled science.

Mechanism / Area of Study

GLP-1 receptor pathway

GLP-1 receptor activation in pancreatic beta-cell models amplifies glucose-dependent insulin secretion and inhibits glucagon release in alpha-cell models; central GLP-1 pathways are studied for satiety signalling.

GIP receptor pathway

GIP receptor signalling is studied in beta cells and adipose tissue. GIP agonism appears to modulate insulin secretion and adipose lipid handling in preclinical models; its central effects are less fully characterised.

Dual agonism

Tirzepatide engages both receptors with engineered imbalance (stronger GIP than GLP-1 potency in vitro). Research interest centres on whether combined signalling produces effects beyond either pathway alone — the core question of dual-agonist research.

Published Research (selection)

• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216.
• Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503-515.
• Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist: proof-of-concept trial. Lancet 2018;392:2180-2193.
• Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5:e140532.

These publications describe clinical and pharmacological research. They are references for scientific context, not guidance of any kind.

Documentation

Batch-specific Certificates of Analysis, where available, are linked from this page and the VQ COA library. A COA documents identity and purity testing for a specific batch; it does not describe biological activity.

Important Information

For in-vitro laboratory research only. Not for human or veterinary use. VQ Health provides no dosing, administration, protocol or treatment information. Discussion of published clinical research above is for scientific education and does not constitute advice or an endorsement of any non-research use.